Supplements

2023 Rare Diseases Report: Cancers


 

This edition of Rare Diseases Report: Cancers highlights the latest breakthroughs and remaining unmet needs in the management of rare cancers. In addition to celebrating the great progress that has been made in recent years, we also discuss new challenges, such as how the healthcare system can prepare to manage the growing number of rare cancer survivors who are living longer due to improvements in disease management.

INTRODUCTION

NORD: Making Progress Through Collaboration
By Katie Kowalski, MPH

IN THIS ISSUE

The Complex Challenge of Survival After HPV-Associated Oropharyngeal Cancer
By Vlad C. Sandulache, MD, PhD

Progress in Ovarian Cancer: Discovery of Fallopian Tube Involvement
By Ronny Drapkin, MD, PhD

An Evolving Understanding of Adenosquamous Carcinoma of the Lung
By Rajwanth Veluswamy, MD, MSCR

Gastrointestinal Stromal Tumor: Reflecting on 2 Decades of Clinical Advancements
By Jason K. Sicklick, MD, FACS

Progress in Treating Testicular Cancer
By Liang Cheng, MD

Strategies to Improve Long-Term Outcomes in Younger Patients with Hodgkin Lymphoma
By Ann LaCasce, MD, MMSc

Targeted Therapies in Younger and Older Patients with Mantle Cell Lymphoma
By Reem Karmali, MD, MS

Advances in Management of Relapsed/Refractory Hairy Cell Leukemia
By Robert J. Kreitman, MD

Treatment Needs of Older Adults With Newly Diagnosed Acute Myeloid Leukemia
By Harry Erba, MD, PhD

Progress in Management of Advanced Acute Lymphocytic Leukemia in Children
By Susan Colace, MD, MSCI

Recommended Reading

Cancer clinics begin to accommodate patients demanding new cancer detection tests
MDedge Hematology and Oncology
Mastocytosis: Rare, underdiagnosed, potentially fatal
MDedge Hematology and Oncology
VEXAS syndrome: More common, variable, and severe than expected
MDedge Hematology and Oncology
Maternal infection in pregnancy ups risk for childhood leukemia?
MDedge Hematology and Oncology
Autoantibodies signal reduced cancer risk in dermatomyositis
MDedge Hematology and Oncology
CT results in myositis inform cancer screening strategies
MDedge Hematology and Oncology
Cancer, heart disease vaccines may be ready by 2030, Moderna says
MDedge Hematology and Oncology
Pembrolizumab monotherapy effective for rare melanoma
MDedge Hematology and Oncology
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
MDedge Hematology and Oncology
Huge underuse of germline testing for cancer patients
MDedge Hematology and Oncology